(lp0
S'Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1159445 ... Business Wire  - Mar 23, 2012 NEWTON, Mass.----Galectin Therapeutics Inc.  today announced the pricing of an underwritten public offering of 1,159,445 units at a price to the public of $9.00 per unit, with each unit consisting of two common voting&nbsp;...'
p1
aS"BRIEF-Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics Reuters - Jan 18, 2017 LONDON, March 14 Unilever CEO Paul Polman said there should be a level playing field for companies facing takeover bids such as Kraft Heinz's failed $143 billion attempt to buy the Anglo-Dutch company, the FT reported on Tuesday."
p2
aS'GALECTIN THERAPEUTICS INC.  Files An 8-K Entry into a Material ... Market Exclusive - Dec 29, 2016 Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer.'
p3
aS'Looking at the Gauges on Galectin Therapeutics Inc.  Rives Journal - Oct 31, 2016 Technical Traders may be interested in looking at the indicator levels on shares of Galectin Therapeutics Inc. . The 14-day ADX for Galectin Therapeutics Inc.  is currently 21.61. In general, an ADX value from 0-25 would signal an absent ...'
p4
aS"analysts Recommendations: Galectin Therapeutics, Inc.  News Oracle - Feb 7, 2017 Galectin Therapeutics, Inc.  will report its next earnings on Mar 13 - Mar 17 . The company reported the earnings of $-0.19/Share in the last quarter where the estimated EPS by analysts was $-0.22/share. The difference between the&nbsp;...Investors Watch-List Stock: Galectin Therapeutics, Inc.'s  - Street UpdatesGalectin Therapeutics to Present at BIO CEO &amp; Investor Conference - PharmiWeb.com "
p5
aS'Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH ... PharmiWeb.com  - Feb 1, 2017 01, 2017  -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned expenditures through 2017 and&nbsp;...'
p6
aS"Healthcare Gainers: Conatus Pharmaceuticals Inc. , Galectin ... Benchmark Monitor - Feb 7, 2017 At the movement Conatus Pharmaceuticals Inc.  is under coverage by number of analysts. Buy rating has been given by 2 analysts to the company stock whereas no analyst given UNDERPERFORM rating to stock and no analyst given HOLD&nbsp;...Noteworthy Gainer Stock Inside Traders Radar: Conatus Pharmaceuticals Inc.'s ... - WsNews 4investors"
p7
aS'Gainers &amp; Losers Of The Day: EYES, SGNL, NEOT, DMTX, MBRX... Nasdaq - Feb 8, 2017 Non-transferable subscription rights to purchase units, composed of a share of Second Sight common stock and a five-year warrant to purchase an additional share of common stock, will be issued in the offering.'
p8
aS'Allergan to buy Tobira in push for fatty liver disease drugs Reuters UK - Sep 20, 2016 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity. Just ...'
p9
aS'MUSTANG BIO, INC.  Files An 8-K Entry into a Material Definitive ... Market Exclusive - Dec 6, 2016 Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is&nbsp;...'
p10
a.